These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 38092371)
1. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma. Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371 [TBL] [Abstract][Full Text] [Related]
2. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis. Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020 [TBL] [Abstract][Full Text] [Related]
3. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343 [TBL] [Abstract][Full Text] [Related]
4. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210 [TBL] [Abstract][Full Text] [Related]
5. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature. Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009 [TBL] [Abstract][Full Text] [Related]
7. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies. Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma. Lynggård LA; Panou V; Szejniuk W; Røe OD; Meristoudis C J Am Soc Cytopathol; 2022; 11(6):385-393. PubMed ID: 35945149 [TBL] [Abstract][Full Text] [Related]
10. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. Terra S; Roden AC; Yi ES; Aubry MC; Boland JM Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336 [TBL] [Abstract][Full Text] [Related]
11. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features. Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798 [TBL] [Abstract][Full Text] [Related]
12. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220 [TBL] [Abstract][Full Text] [Related]
13. Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma. Davidson B; Holth A; Hummel C; Flatmark K; Torgunrud A Appl Immunohistochem Mol Morphol; 2024 Jul; 32(6):280-284. PubMed ID: 38812360 [TBL] [Abstract][Full Text] [Related]
14. Utility of BAP1, p16, and Methylthio-Adenosine Phosphorylase Immunohistochemistry in Cytological and Histological Samples of Pleural Mesotheliomas. Amacher V; Bode PK; Moch H; Lenggenhager D; Vrugt B Acta Cytol; 2023; 67(4):444-450. PubMed ID: 36889303 [TBL] [Abstract][Full Text] [Related]
15. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma. Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810 [TBL] [Abstract][Full Text] [Related]
16. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas. Berg KB; Dacic S; Miller C; Cheung S; Churg A Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257 [TBL] [Abstract][Full Text] [Related]
17. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Berg KB; Churg AM; Cheung S; Dacic S Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740 [TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788 [TBL] [Abstract][Full Text] [Related]
19. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas. Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829 [TBL] [Abstract][Full Text] [Related]
20. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma. Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]